Hope for rhabdomyosarcoma: vitamin a derivative joins chemo in new trial
NCT ID NCT07355855
First seen Jan 29, 2026 · Last updated Jun 20, 2026 · Updated 23 times
Summary
This Phase 2 trial tests whether adding all-trans retinoic acid (a vitamin A derivative) to standard VAC chemotherapy improves outcomes for 106 people aged 14-60 with intermediate-to-high-risk rhabdomyosarcoma, a rare muscle cancer. Participants will receive the drug combo in 21-day cycles, and researchers will track survival, tumor response, and side effects. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan university cancer hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
all-trans retinoic acid (ATRA) combined with VAC chemotherapy (vincristine, dactinomycin, cyclophosphamide)
What this could lead to
If this works, it could improve survival and disease control for people with intermediate-to-high-risk rhabdomyosarcoma, offering a more effective treatment option.
What could go wrong
This is an early Phase 2 trial with only 106 participants, so results may not apply to everyone. The combination may cause side effects like those from standard chemotherapy, and it is not yet proven to be better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.